预约演示
更新于：2025-07-19
Fenretinide
芬维A胺
更新于：2025-07-19
概要
基本信息
最高研发阶段临床2/3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C26H33NO2 |
InChIKeyAKJHMTWEGVYYSE-FXILSDISSA-N |
CAS号65646-68-6 |
关联
37
项与 芬维A胺 相关的临床试验NCT06922539
A Phase 1a/1b Trial in Relapsed/Refractory Small Cell Lung Cancer to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion
This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
开始日期2025-06-01 |
申办/合作机构- |
NCT04234048
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
开始日期2023-12-18 |
申办/合作机构- |
NCT06181760
A Phase 1a, Randomized, Double-blind Placebo-controlled Study to Evaluate Safety and Tolerability and to Characterize the Pharmacokinetic Profile of Single Ascending Doses of Fenretinide Oral Capsules in Healthy Adult Volunteers
The goal of this clinical trial was to learn about a single dose of fenretinide in healthy volunteers, in both a fasted and fed state. The main questions to answer were:
* How well is a single dose of fenretinide tolerated? AND
* How is a single dose of fenretinide metabolized in healthy volunteers?
Participants will be asked to:
* Remain confined in a clinical research unit for 5 days after dosing.
* Provide blood samples for intense PK sampling and safety labs.
* Fast for 10 hours prior to administration of study drug (fasted cohorts).
* Consume a high fat meal prior to administration of study drug (fed cohort).
* Return to the clinic for a single follow-up visit for safety assessments.
The study will compare active fenretinide to placebo to see if fenretinide is more or less tolerable than placebo.
* How well is a single dose of fenretinide tolerated? AND
* How is a single dose of fenretinide metabolized in healthy volunteers?
Participants will be asked to:
* Remain confined in a clinical research unit for 5 days after dosing.
* Provide blood samples for intense PK sampling and safety labs.
* Fast for 10 hours prior to administration of study drug (fasted cohorts).
* Consume a high fat meal prior to administration of study drug (fed cohort).
* Return to the clinic for a single follow-up visit for safety assessments.
The study will compare active fenretinide to placebo to see if fenretinide is more or less tolerable than placebo.
开始日期2023-11-22 |
申办/合作机构 |
100 项与 芬维A胺 相关的临床结果
登录后查看更多信息
100 项与 芬维A胺 相关的转化医学
登录后查看更多信息
100 项与 芬维A胺 相关的专利（医药）
登录后查看更多信息
1,523
项与 芬维A胺 相关的文献（医药）2025-08-01·Current Drug Delivery
Development of Mixed Micelles for Enhancing Fenretinide Apparent Solubility and Anticancer Activity Against Neuroblastoma Cells
Article
作者: Alfei, Silvana ; Marimpietri, Danilo ; Zorzoli, Alessia ; Zuccari, Guendalina
Introduction/Objectives::
The purpose of the study was to evaluate the suitability of
mixed micelles prepared with D-α-tocopheryl polyethylene glycol succinate (TPGS) and 1,2-
distearoyl-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-PEG) to
encapsulate the poorly soluble anticancer drug fenretinide (4-HPR).
Methods::
After assaying the solubilization ability of the surfactants by the equilibrium method, the
micelles were prepared using the solvent casting technique starting from different 4-HPR:TPGS:
DSPE-PEG w/w ratios. The resulting formulations were investigated for their stability under storage
conditions and upon dilution, modelling the reaching of physiological concentrations after intravenous
administration. The characterization of micelles included the determination of DL%, EE %,
particle size distribution, Z-potential, and thermal analysis by DSC. The cytotoxicity studies were
performed on HTLA-230 and SK-N-BE-2C neuroblastoma cells by the MTT essay.
Results::
The colloidal dispersions showed a mean diameter of 12 nm, negative Zeta potential, and a
narrow dimensional distribution. 4-HPR was formulated in the mixed micelles with an encapsulation
efficiency of 88% and with an increment of the apparent solubility of 363-fold. The 4-HPR entrapment
remained stable up to the surfactants’ concentration of 2.97E-05 M. The loaded micelles exhibited
a slow-release behaviour, with about 28% of the drug released after 24 h. On the most resistant
SK-N-BE-2C cells, the encapsulated 4-HPR was significantly more active than free 4-HPR in reducing
cell viability.
Conclusion::
Loaded micelles demonstrated their suitability as a new adjuvant tool potentially useful
for the treatment of neuroblastoma.
2025-03-01·Journal of Cosmetic Dermatology
A Functional Skincare Formulation Mixed With Retinyl Propionate, Hydroxypinacolone Retinoate, and Vitamin C on Antiaging and Whitening Han Women in Shanghai, China
Article
作者: Qiao, Jian ; Chen, Min ; Bian, Qianjin ; Zhang, Fan ; Fang, Wei
ABSTRACT:
Background:
Human skin is remodeled as a result of aging. Retinoids (or retinol derivatives) can intervene in this process, which can be optimally formulated and concentrated by providing maximum antiaging effects with minimal irritation.
Aims:
To determine the optimal ratio of two retinol derivatives hydroxypinacolone retinoate (HPR), retinol propionate (RP), and vitamin C (VitC) in dermal remodeling and preventing skin aging, and to investigate their synergistic antiaging and whitening effects in vitro and in vivo.
Methods:
An in vitro model of human skin fibroblast (HSF) was established to evaluate the cellular viability of VitC and/or RP/HPR treatment. We quantified the expression of genes associated with antiaging and retinol receptors in HSFs treated with VitC and/or RP/HPR. The research was conducted on 120 volunteer women to quantify the antiaging efficacy of functional skincare formulation.
Results:
A combination of VitC and RP/HPR at a weight ratio of 40:3 achieved the optimal and safe antiaging performance in vitro. Transcription of aging‐associated genes and the release of elastin and senescence‐associated secretory phenotypes (SASPs) increased significantly after UV irradiation, whereas VitC and RP/HPR cotreatment can inhibit this increase. The synergistic stimulation of VitC and RP/HPR cotreatment showed higher efficacy in the recovery ability of skin injury.
Conclusions:
Our results indicated the advanced skin antiaging and whitening effects of VitC and RP/HPR cotreatment in vitro and in vivo. A combination of VitC and RP/HPR is a potent strategy to postpone skin aging and improve skin whitening for middle‐aged women.
Trial Registration:
ClinicalTrials.gov identifier: 2020‐LS‐023
2025-01-01·Journal of Cystic Fibrosis
Efficacy and safety of LAU-7b in a Phase 2 trial in adults with cystic fibrosis
Article
作者: Zuckerman, Jonathan B ; Colin, Patrick ; Konstan, Michael W ; Kianicka, Irenej ; Middleton, Peter G ; Kotsimbos, Tom ; Radzioch, Danuta ; Polineni, Deepika ; Matouk, Elias ; Lands, Larry C ; Houle, Jean-Marie ; Liou, Theodore G ; Chmiel, James F ; Potvin, Diane ; Pislariu, Radu ; Bilodeau, Lara ; Nasr, Samya Z
BACKGROUND:
Lung inflammation is associated with tissue damage in cystic fibrosis (CF). LAU-7b, a novel oral drug candidate, was shown to control inflammation and stabilize CFTR protein in the epithelial membrane during inflammatory stress in preclinical models of CF.
METHODS:
A double-blind, randomized, placebo-controlled Phase 2 study was conducted to evaluate efficacy and safety of LAU-7b in adults with CF. LAU-7b or placebo was administered over 24 weeks as six 21-day treatment cycles each separated by 7 days. The primary efficacy endpoint was the absolute change from baseline in percent predicted forced expiratory volume in 1 second (ppFEV1) at 24 weeks.
RESULTS:
A total of 166 subjects received at least one dose of study drug (Intent-To-Treat population, ITT), of which 122 received ≥5 treatment cycles (Per-Protocol population, PP). Both treatment arms showed a mean lung function loss at 24 weeks of 1.18 ppFEV1 points with LAU-7b and 1.95 ppFEV1 with placebo, a 0.77 ppFEV1 (40 s) difference, p=0.345, and a 0.95 ppFEV1 (49 %) difference in the same direction in PP population, p=0.263. Primary analysis of mean ppFEV1 through 24 weeks showed differences of 1.01 and 1.23 ppFEV1, in the ITT (65 % less loss, p=0.067) and PP populations (78 % less loss, reaching statistical significance p=0.049), respectively. LAU-7b had an acceptable safety profile.
CONCLUSION:
Although the study did not meet its primary efficacy endpoint in the ITT population, LAU-7b was generally well tolerated and showed evidence of preservation of lung function to support further development.
23
项与 芬维A胺 相关的新闻（医药）2025-04-08
GROSSE POINTE FARMS, Mich., April 8, 2025 /PRNewswire/ -- SciTech Development, Inc., a clinical-stage oncology company pioneering innovative cancer therapeutics, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for "A Phase 1a/b Trial in Relapsed/Refractory Small Cell Lung Cancer (SCLC) to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension for Intravenous Infusion." This milestone greenlights SciTech to begin recruiting patients and initiates another Phase 1a/b clinical trial of ST-001, a novel nanoparticle drug designed to deliver fenretinide effectively to cancer cells.
The FDA's approval follows a thorough safety review, with the agency stating, "We have completed our safety review of your application and have concluded that you may proceed with your proposed clinical investigation of fenretinide phospholipid suspension (ST-001) for small cell lung cancer." This decision marks a significant step forward in SciTech's mission to address unmet needs in oncology, particularly for patients with relapsed or refractory SCLC, a notoriously aggressive disease with limited treatment options.
Leading the trial, as Principal Investigator, is Greg Kalemkerian, MD, a renowned thoracic oncologist at the University of Michigan. "Small cell lung cancer remains a formidable challenge with few effective therapies for patients who relapse or don't respond to initial treatment," said Dr. Kalemkerian. "ST-001 represents a promising approach, and I'm excited to oversee this trial to evaluate its safety and potential for SCLC patients who desperately need new options."
ST-001 nanoFenretinide leverages SciTech's patented drug delivery platform to overcome fenretinide's historical bioavailability challenges, delivering high doses intravenously with enhanced efficacy and reduced toxicity. The Phase 1a/b trial will assess the drug's safety, pharmacology, and maximum tolerated dose, paving the way for further development in SCLC and potentially other cancers.
Building on prior success in a Phase 1a trial for T-cell non-Hodgkin lymphoma - where ST-001 demonstrated favorable pharmacokinetics and early signs of efficacy - SciTech is preparing to launch the SCLC trial in Q2/3 2025. The company anticipates that this trial will further validate the drug's broad therapeutic potential.
"We are thrilled about the FDA's approval of our IND for ST-001 in SCLC," said Earle T. Holsapple, CEO of SciTech Development. "This is a pivotal moment that brings us closer to offering a transformative treatment option for patients facing this devastating disease. "Our team's dedication to advancing ST-001's potential through innovative nanotechnology is showing promising results, and we're eager to see its impact in the clinic."
About SciTech Development, Inc.
SciTech Development, Inc., headquartered in Grosse Pointe Farms, Michigan, is a clinical-stage pharmaceutical company focused on revolutionizing cancer treatment through its proprietary drug delivery platform. ST-001 nanoFenretinide, its lead candidate, combines fenretinide with biocompatible phospholipids to target hard-to-treat cancers, offering hope to patients worldwide.
For more information, please visit or contact:
Media Contact: David Schaffer | +1-727-278-8188 | [email protected]
Disclaimer: This press release contains forward-looking statements based on current expectations. Actual results may differ due to risks and uncertainties. SciTech undertakes no obligation to update these statements beyond legal requirements.
SOURCE SciTech Development, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
临床1期临床申请
2025-01-13
**Encouraging
Data from Accelerated Trial Supports Progress for T-cell Non-Hodgkin Lymphoma.**
DETROIT, Jan. 13, 2025 /PRNewswire/ -- SciTech Development, a clinical-stage pharmaceutical company specializing in oncology, is pleased to announce the initiation of the next stage of its clinical trial for their lead drug candidate,
ST-001 nanoFenretinide (ST-001)
. This milestone follows the successful completion of the accelerated safety and dose-escalation stage, where ST-001 demonstrated exceptional safety, tolerability, and pharmacokinetic performance.
Advancing the Phase 1a Trial with Clear Clinical Objectives
The continuation of the ST-001 clinical trial aims to achieve several critical clinical objectives:
Confirm that ST-001 achieves previously reported clinical response rates.
Determine the pharmacological profile of intravenous fenretinide delivered using SciTech's novel nanoparticle delivery system, designed for drugs with poor water solubility.
Determine the recommended treatment dose (RTD) to evaluate disease activity and response rates in the follow-on Phase 1b trial and the planned trial in Small Cell Lung Cancer.
"The success of our accelerated Phase 1a trial marks a pivotal milestone, driving ST-001 into the next critical stage of development," said Earle Holsapple, CEO of SciTech Development. "We are thrilled about the potential of ST-001 nanoFenretinide and its promise to transform treatment outcomes for patients battling cancers such as T-cell Non-Hodgkin Lymphoma."
About ST-001 nanoFenretinide
ST-001 nanoFenretinide is a patented nanoparticle IV formulation that combines the drug fenretinide with biocompatible phospholipids. This groundbreaking new investigational drug overcomes bioavailability challenges, enhances therapeutic efficacy, and minimizes toxicity in cancer patients. Powered by SciTech's advanced delivery platform, ST-001 enables rapid delivery of effective doses of fenretinide to cancer cells, marking a breakthrough in hard-to-treat cancers.
Encouraging Early Results in Phase 1a Accelerated Trial
During the accelerated stage of the trial, ST-001 achieved significant milestones:
Patient Enrollment is Complete for the accelerated stage of the clinical trial marking a significant accomplishment for patients with this rare disease.
Therapeutic Responses Observed: Patients demonstrated partial responses and stable disease, marking an important step for trial advancement.
Excellent Tolerability for ST-001 across all dose levels to date.
Outstanding Pharmacokinetics: The nanoparticle delivery platform overcame longstanding bioavailability challenges, ensuring efficient delivery of fenretinide to tissues.
Future Direction for ST-001 nanoFenretinide
Building on the success of the accelerated Phase 1a stage, the trial begins detailed evaluation of clinical activity and response rates in T-cell lymphomas. The trial is actively underway at nine renowned medical centers across the country. Click here to learn more about the locations and patient trial criteria. Additionally, a separate trial targeting Small Cell Lung Cancer utilizing ST-001 is scheduled to begin in Q2 2025.
About SciTech Development, Inc.
SciTech Development, Inc., headquartered in Michigan, is an oncology focused, clinical-stage pharmaceutical company led by a world-class team. SciTech is committed to developing innovative, effective, and affordable cancer therapeutics that address unmet medical needs to bring hope to patients around the globe. To learn about SciTech and our latest advancements, please visit .
Read the latest Press Release announcing "Promising Preliminary Results from the Phase 1a Accelerated Trial".
Company Contact:
David Schaffer
Investor Relations
[email protected]
(727) 278-8118
SOURCE SciTech Development, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
临床1期
2024-12-19
A case study on how a pharmaceutical company specializing in cystic fibrosis treatments turned to DelveInsight for comprehensive analysis and insights into the digital cystic fibrosis landscape in the UK. DelveInsight identified key Digital Opinion Leaders (DOLs) and synthesized their opinions, enabling the client to strategically leverage these insights for drug development, marketing, and patient advocacy, ensuring a competitive edge in the cystic fibrosis market.
LAS VEGAS, Dec. 19, 2024 /PRNewswire/ -- DelveInsight, a leader in healthcare competitive intelligence and consulting company, published a success study on Digital Opinion Leader (DOL) Analysis in the
Cystic Fibrosis Market
. A pharmaceutical company specializing in cystic fibrosis treatments approached DelveInsight to conduct an in-depth analysis of DOLs in the UK. The client sought to identify key digital influencers and understand their perspectives on cystic fibrosis treatments, leveraging these insights to inform drug development, marketing strategies, and patient advocacy efforts.
Cystic fibrosis is a life-limiting autosomal recessive genetic disorder that primarily affects the lungs and digestive system, caused by mutations in the CFTR gene. According to DelveInsight's latest Cystic Fibrosis Market and Epidem Forecast Report, the estimated total diagnosed prevalent cases of cystic fibrosis in the
7MM in
2023 were
~68K cases. The
UK had the highest number of
diagnosed cystic fibrosis cases, with nearly
11K, followed by France with
7.5K and Germany with
7K. In the
EU4 and the UK, the cystic fibrosis market size was nearly
USD 7 billion, accounting for almost
39.4% of the total
7MM market size in
2023. This is expected to increase
significantly by 2034.
Download the Sample Report to Explore Future Trends in the
Cystic Fibrosis Market
In the field of cystic fibrosis,
DOLs play a significant role in shaping perceptions and influencing the direction of treatment, policy, and patient care. These are influential healthcare professionals or researchers who have an active online presence and contribute to discussions, research, and advocacy. For pharmaceutical companies developing cystic fibrosis treatments, understanding the DOL landscape is crucial for gaining insights into market dynamics and stakeholder perceptions and identifying strategic opportunities for drug development, marketing, and patient advocacy.
Several medications have been approved to manage cystic fibrosis, with therapies targeting the CFTR protein to correct its defects. One of the most groundbreaking treatments is TRIKAFTA, a combination of
elexacaftor, tezacaftor, and ivacaftor, which has revolutionized cystic fibrosis treatment by improving lung function in patients with specific genetic mutations. Other notable drugs include
SYMDEKO (tezacaftor/ivacaftor) and ORKAMBI (lumacaftor/ivacaftor), which also target the CFTR protein. These therapies aim to address the root cause of the disease, improving symptoms and quality of life for patients. However, despite these advancements, the current treatment landscape still faces challenges, such as variability in treatment efficacy and accessibility to newer therapies for certain patient populations.
The pipeline for cystic fibrosis treatments continues to evolve, with several promising drugs in the cystic fibrosis pipeline.
Ensifentrine (Verona Pharmaceuticals) is a dual inhibitor of the enzymes responsible for inflammation and mucus production in the lungs, showing potential as an add-on therapy for patients with CF.
VX-121/TEZ/VX-561 (Vertex Pharmaceuticals) is another exciting treatment, combining triple therapy to enhance CFTR function and improve lung function.
LAU-7b (Laurent Pharmaceuticals Inc.) aims to restore CFTR function and reduce inflammation.
Lonodelestat (Pari Pharma GmbH) is being investigated for its ability to reduce neutrophil elastase and inflammation in the lungs of CF patients. These drugs, if successful, could significantly improve treatment options and outcomes for CF patients.
Several companies are at the forefront of developing treatments for cystic fibrosis.
Eloxx Pharmaceuticals, Inc. focuses on treatments that aim to restore protein function in CF patients with specific genetic mutations. Vertex Pharmaceuticals is a leader in the CF market, with therapies like
TRIKAFTA and ongoing pipeline developments.
Santhera Pharmaceuticals is exploring potential treatments to address pulmonary issues in CF patients.
DelveInsight helped the client by curating insights from the digital cystic fibrosis landscape and analyzing the opinions of key digital influencers. By identifying and analyzing these DOLs, DelveInsight provided actionable insights and strategic recommendations for the client. The company gained a deeper understanding of the market dynamics, stakeholder perceptions, and the evolving digital landscape surrounding cystic fibrosis. These insights were invaluable for informing drug development strategies, understanding the gaps, patient burden,, and patient advocacy initiatives. Armed with comprehensive information on DOLs and their impact, the client was better equipped to make informed decisions, enhance patient engagement, and improve the overall market approach for cystic fibrosis treatments.
Our client approached us with multiple objectives:
Understand the DOL Landscape in the UK for cystic fibrosis.
Identify Key Digital Opinion Leaders influencing discussions about cystic fibrosis.
Analyze the Opinions of DOLs on treatment options and emerging therapies.
Leverage Insights to refine drug development, marketing strategies, and patient advocacy efforts.
Outcome of DelveInsight's Digital Opinion Leader Analysis:
We identified and profiled key digital opinion leaders (DOLs) in the UK cystic fibrosis community, focusing on those with strong online presence, high engagement, and CF expertise.
Through content analysis, we gained insights into opinions, trends, and key areas like treatment, patient care, advocacy, and research within the CF community.
We mapped the CF digital ecosystem, highlighting connections and interactions between DOLs and stakeholders revealing network dynamics and engagement patterns.
We assessed the impact of DOLs using metrics like follower count, engagement rate, and content virality, helping clients prioritize engagement strategies and collaborations.
DelveInsight specializes in comprehensive Key Opinion Leader (KOL) and Digital Opinion Leader (DOL) opinion analysis, offering deep insights into industry trends, expert perspectives, and influencer dynamics. Our expertise enables clients to identify and understand the nerve of the trends by providing analysis through the most impactful thought leaders and digital influencers. By leveraging our tailored strategies and data-driven approaches, we help businesses strengthen their approach, refine decision-making, and amplify their market impact.
Connect with us today to explore how we can support your specific needs and discuss opportunities for strategic engagement.
Request a Proposal Now
!
Why Choose DelveInsight?
DelveInsight offers comprehensive expertise in the respiratory disease domain, providing in-depth market research, consulting services, and pipeline analysis tailored to the evolving needs of the industry. With a sharp focus on respiratory conditions, DelveInsight delivers robust reports covering emerging therapies, market trends, competitive landscapes, and unmet needs. DelveInsight's respiratory-specific solutions empower stakeholders to make data-driven decisions, optimize their R&D efforts, and seize growth opportunities in the dynamic and rapidly advancing respiratory disease market.
Market Assessment Services in the Genetic Disorders Segment, DelveInsight, provide a 360-degree view of the market landscape. Our expertise includes
epidemiology-based market forecasts up to 2034, offering precise insights into current and future market share uptake of emerging therapies. These forecasts, combined with detailed analyses of emerging trends, competitive dynamics of the pipeline therapies, and unmet needs, enable stakeholders to strategize effectively and identify growth opportunities. Whether it's the pipeline analysis, pricing strategies, or competitive benchmarking, DelveInsight delivers actionable intelligence tailored to your goals.
Contact us Today to discuss how our services can drive success in your endeavors within the genetic disorder market.
Competitive Intelligence Services Tailored to Genetic Disorder Domain: DelveInsight's competitive intelligence services provide real-time, accurate insights across the different therapeutic domains and genetic disorders being one of our fortes, providing detailed insights into advancements across rare and inherited conditions such as cystic fibrosis, Duchenne muscular dystrophy, and sickle cell anemia etc to name a few. Our services analyze competitors' pipelines, clinical trial progress, gene and cell therapy innovations, and market entry strategies, as well as regulatory updates and patent landscapes specific to genetic disorders. This intelligence enables stakeholders to identify emerging threats, uncover growth opportunities, and develop targeted strategies to remain competitive in this evolving therapeutic area.
Connect with us today to explore how we can help you succeed in the genetic disorders market.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform , PharmDelve
.
Contact Us
Shruti Thakur
[email protected]
+14699457679
Logo:
SOURCE DelveInsight Business Research, LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
上市批准
100 项与 芬维A胺 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新冠肺炎后遗症 | 临床3期 | 加拿大 | 2023-11-20 | |
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-06-29 | |
| BRCA突变阳性乳腺癌 | 临床3期 | 意大利 | 2009-12-01 | |
| HR阳性乳腺癌 | 临床3期 | 美国 | 1995-10-01 | |
| 乳腺癌 | 临床3期 | - | - | |
| 乳腺癌 | 临床3期 | - | - | |
| 登革热 | 临床2期 | 美国 | 2024-09-05 | |
| 囊性纤维化 | 临床2期 | 美国 | 2018-11-05 | |
| 囊性纤维化 | 临床2期 | 澳大利亚 | 2018-11-05 | |
| 囊性纤维化 | 临床2期 | 加拿大 | 2018-11-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | - | 窪鑰構製願鏇醖簾醖鑰(窪選醖餘鏇齋憲遞壓壓) = earlier-than-anticipated stable disease and partial responses - one initial and one confirmed. 壓遞夢鏇襯鑰膚觸範鑰 (淵艱鬱遞選壓鑰鹹範觸 ) 更多 | 积极 | 2024-12-03 | |||
临床2期 | 166 | (LAU-7b) | 網構構鏇憲廠獵獵鹽餘(獵顧醖鹽鹹鬱窪鏇齋窪) = 艱鹽觸鹽廠獵衊憲鬱廠 顧齋構獵鏇範衊鹽淵繭 (繭鬱築繭糧襯膚鹽艱餘, 衊憲淵膚蓋觸艱窪繭築 ~ 襯願鹽製壓簾願壓鹽顧) 更多 | - | 2024-10-09 | ||
Placebo oral capsule (Placebo) | 網構構鏇憲廠獵獵鹽餘(獵顧醖鹽鹹鬱窪鏇齋窪) = 廠壓願鏇衊醖醖衊艱簾 顧齋構獵鏇範衊鹽淵繭 (繭鬱築繭糧襯膚鹽艱餘, 築膚襯鹹膚範襯構鬱願 ~ 鏇鏇構膚蓋鏇鑰醖鹽鏇) 更多 | ||||||
临床1期 | 16 | Fenretinide | 選製鬱鬱遞範夢衊顧鑰(艱鬱齋憲壓鏇廠夢鏇襯) = 壓淵憲遞廠鬱窪窪鹹廠 窪醖鹽獵膚鹽觸遞顧壓 (構鏇壓積鏇夢壓觸齋遞 ) | 不佳 | 2023-08-01 | ||
临床2期 | 166 | 壓壓範廠構醖膚鏇製鑰(鏇顧淵齋製蓋膚醖醖鏇): difference = 1.23, P-Value = 0.0486 | 积极 | 2022-11-03 | |||
Placebo | |||||||
临床2期 | 21 | (A- Fenretinide) | 窪顧鹹齋夢網衊積鏇繭(鬱顧廠壓窪遞鏇顧鏇選) = 艱蓋鹹獵鹽廠淵夢築憲 蓋積鹽鏇遞構簾鬱構鹽 (繭齋製遞製壓夢鑰網淵, 鏇齋願選糧鏇觸遞鹹襯 ~ 艱獵選願鹹製鹽製範淵) 更多 | - | 2021-02-10 | ||
placebo (B-Placebo) | 窪顧鹹齋夢網衊積鏇繭(鬱顧廠壓窪遞鏇顧鏇選) = 艱窪餘壓繭觸齋構醖選 蓋積鹽鏇遞構簾鬱構鹽 (繭齋製遞製壓夢鑰網淵, 選範糧網積膚醖廠網觸 ~ 觸築顧廠憲築廠壓餘襯) 更多 | ||||||
临床1/2期 | 32 | 鹽廠鏇觸簾選鬱窪構構(鹹醖範顧糧選顧淵鑰鑰) = No dose-limiting toxicities were observed. 艱鬱築簾築壓衊積襯艱 (艱觸鬱觸淵築艱築鹽範 ) 更多 | 积极 | 2017-02-01 | |||
临床2期 | 23 | 鹹鏇獵鬱獵範鹹製襯襯 = 艱範網鹹選觸齋衊壓構 鹹繭鑰範遞餘鬱鹹獵餘 (鏇壓遞繭鹽壓選衊廠壓, 繭繭憲範製顧繭願繭憲 ~ 襯遞鹹鑰淵鏇窪衊憲製) 更多 | - | 2015-03-06 | |||
临床1/2期 | 32 | (Fenretinide and Rituximab) | 鹹鏇製夢鏇構廠蓋遞鏇 = 蓋鏇鬱淵選網廠鬱網鹽 糧淵獵願觸築繭膚網衊 (齋膚遞築鹹膚鹹簾鏇積, 齋願繭顧膚鬱鬱鹽膚憲 ~ 鹹夢鹹醖憲願鑰鑰鏇餘) 更多 | - | 2014-10-06 | ||
(Fenretinide and Rituximab (Rituximab Naive)) | 齋衊鬱鑰鏇襯築艱襯醖 = 憲構獵簾構鏇網選淵築 簾築鑰選範網餘鹽築衊 (獵網積鑰餘製鹹膚遞簾, 壓網膚簾鬱積糧觸憲選 ~ 範憲繭夢憲艱齋構襯醖) | ||||||
临床1期 | 80 | 觸蓋壓壓鑰鬱壓夢糧鹹(觸艱鏇鹽膚齋壓遞夢廠) = 遞積簾窪鹽簾網觸齋壓 遞鬱襯衊網顧製憲網選 (鏇衊衊觸網積鑰艱獵衊, 1.35 ~ 36.9+) 更多 | - | 2014-05-20 | |||
簾鑰餘積壓積鏇鏇選夢(膚繭夢艱獵膚網壓鹹鹹) = 鹹顧鹹鏇艱網築築淵衊 選繭簾壓積鏇構獵選構 (選憲鹹簾膚鑰醖範蓋網, 14.6 ~ 22.1) | |||||||
临床1期 | 25 | 廠築膚廠積構壓襯網夢(顧餘艱獵選獵範窪顧夢) = Reversible hypertriglyceridemia related to the intralipid vehicle accounted for 6/7 DLTs 夢廠壓簾積廠窪鑰鏇顧 (蓋網顧襯繭憲廠齋獵築 ) | - | 2012-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用